Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
Bouwstra R, He Y, de Boer J, Kooistra H, Cendrowicz E, Fehrmann RSN, Ammatuna E, Zu Eulenburg C, Nijland M, Huls G, Bremer E, van Meerten T. Bouwstra R, et al. Among authors: nijland m. Cancer Immunol Res. 2019 Oct;7(10):1663-1671. doi: 10.1158/2326-6066.CIR-18-0781. Epub 2019 Aug 13. Cancer Immunol Res. 2019. PMID: 31409608
Relapse in stage I(E) diffuse large B-cell lymphoma.
Nijland M, Boslooper K, van Imhoff G, Kibbelaar R, Joosten P, Storm H, van Roon EN, Diepstra A, Kluin-Nelemans HC, Hoogendoorn M. Nijland M, et al. Hematol Oncol. 2018 Apr;36(2):416-421. doi: 10.1002/hon.2487. Epub 2017 Oct 30. Hematol Oncol. 2018. PMID: 29083044 Free PMC article.
Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis.
Montes de Jesus FM, Kwee TC, Nijland M, Kahle XU, Huls G, Dierckx RAJO, van Meerten T, Gheysens O, Dierickx D, Vergote V, Noordzij W, Glaudemans AWJM. Montes de Jesus FM, et al. Among authors: nijland m. Crit Rev Oncol Hematol. 2018 Dec;132:27-38. doi: 10.1016/j.critrevonc.2018.09.007. Epub 2018 Sep 19. Crit Rev Oncol Hematol. 2018. PMID: 30447925 Free article.
Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma.
Nijland M, Seitz A, Terpstra M, van Imhoff GW, Kluin PM, van Meerten T, Atayar Ç, van Kempen LC, Diepstra A, Kok K, van den Berg A. Nijland M, et al. Cancers (Basel). 2018 Nov 20;10(11):459. doi: 10.3390/cancers10110459. Cancers (Basel). 2018. PMID: 30463380 Free PMC article.
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Bromberg JEC, Issa S, Bakunina K, Minnema MC, Seute T, Durian M, Cull G, Schouten HC, Stevens WBC, Zijlstra JM, Baars JW, Nijland M, Mason KD, Beeker A, van den Bent MJ, Beijert M, Gonzales M, de Jong D, Doorduijn JK. Bromberg JEC, et al. Among authors: nijland m. Lancet Oncol. 2019 Feb;20(2):216-228. doi: 10.1016/S1470-2045(18)30747-2. Epub 2019 Jan 7. Lancet Oncol. 2019. PMID: 30630772 Clinical Trial.
Tumour necrosis as assessed with 18F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements.
Kahle XU, Hovingh M, Noordzij W, Seitz A, Diepstra A, Visser L, van den Berg A, van Meerten T, Huls G, Boellaard R, Kwee TC, Nijland M. Kahle XU, et al. Among authors: nijland m. Eur Radiol. 2019 Nov;29(11):6018-6028. doi: 10.1007/s00330-019-06178-9. Epub 2019 Apr 26. Eur Radiol. 2019. PMID: 31028445 Free PMC article.
MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.
Vermaat JS, Somers SF, de Wreede LC, Kraan W, de Groen RAL, Schrader AMR, Kerver ED, Scheepstra CG, Berenschot H, Deenik W, Wegman J, Broers R, de Boer JD, Nijland M, van Wezel T, Veelken H, Spaargaren M, Cleven AH, Kersten MJ, Pals ST. Vermaat JS, et al. Among authors: nijland m. Haematologica. 2020 Jan 31;105(2):424-434. doi: 10.3324/haematol.2018.214122. Print 2020. Haematologica. 2020. PMID: 31123031 Free PMC article.
200 results